FDA issues approval of Encelto
The FDA has approved revakinagene taroretcel-lwey (brand name, Encelto) for the treatment of adults with idiopathic Macular Telangiectasia type 2 (MacTel). It is the first FDA-approved treatment for Macular Telangiectasia type 2, a neurodegenerative retinal disease that affects the macula, causing a gradual deterioration in central vision. It is characterised by changes in the macular capillary network and atrophy of the neurosensory retina. Encelto employs encapsulated cell therapy technology to deliver continuous doses of ciliary neurotrophic factor to the retina. Please find further information here.
News reported on the 2nd of April 2025 in Catapult’s regulatory round-up, read the entire report here.
OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (20 mai 2025). FDA issues approval of Encelto. ELSIBI. Consulté le 13 janvier 2026 à l’adresse https://doi.org/10.58079/13yk2





